Immediate Effects of External Trigeminal Nerve Stimulation on Motor Dysfunction in Parkinson's Disease
Parkinson's disease (PD), the most common movement disorder, is characterized by motor symptoms including tremor, rigidity, bradykinesia, and postural instability. These symptoms substantially impair quality of life and increase the risk of falls, disability, and accidental injury, representing a major therapeutic challenge.
External trigeminal nerve stimulation (eTNS), a non-invasive neuromodulation technique, has shown promising potential in PD and other movement disorders. A clinical study published in 2017 suggested that trigeminal nerve stimulation may contribute to the alleviation of motor symptoms in patients with PD. In 2023, the U.S. Food and Drug Administration cleared the Portable Neuromodulation Stimulator (PoNS) as an adjunctive treatment for gait impairment caused by multiple sclerosis; the lingual nerve is a branch of the mandibular division of the trigeminal nerve. In the same year, experimental evidence showed that trigeminal nerve stimulation could activate intracranial dopaminergic neurons and modulate dopamine release in mice. These findings suggest substantial potential for eTNS in modulating motor dysfunction in PD, although high-level clinical evidence remains lacking.
This randomized, within-subject study will evaluate the immediate effects of eTNS at different stimulation frequencies on motor dysfunction in patients with PD. Gait parameters will be quantitatively assessed using the IDEEA gait system, together with the MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III), Tinetti Gait Scale, and Hoehn and Yahr Scale.
This within-subject study comprises three 20-min stimulation conditions: 120-Hz eTNS, 40-Hz eTNS, and sham stimulation. Each patient with Parkinson's disease will complete all conditions in a single session in randomized order. Instrumented gait analysis, together with motor and gait rating scales, will be used to quantify immediate post-stimulation changes in gait and motor function relative to baseline.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Rong Li, PhD candidate
- Número de telefone: +86 15529957876
- E-mail: 15529957876@163.com
Locais de estudo
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Xi'an Central Hospital, Department of Neurology
-
Contato:
- Rong Li, PhD candidate
- Número de telefone: +86 15529957876
- E-mail: 15529957876@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Patients with idiopathic Parkinson's disease diagnosed by two neurologists, according to the Chinese diagnostic criteria for Parkinson's disease formulated in 2020 by the Chinese Parkinson's Disease and Movement Disorders Society based on the MDS Clinical Diagnostic Criteria for Parkinson's disease.
- Hoehn and Yahr stage 1-5 in the medication ON state.
- Mini-Mental State Examination (MMSE) score >24.
- Stable antiparkinsonian medication for at least 1 month before the trial.
- No history of orthopedic or musculoskeletal disorders, and no other conditions that may affect balance or gait, such as ophthalmologic disorders.
- No history of epilepsy, intracranial tumors, or other neurological disorders; no severe psychiatric disorders, such as schizophrenia; and no long-term use of antipsychotic medications.
- Age between 40 and 80 years.
- Ability to cooperate with all assessments and eTNS treatment, and provision of written informed consent.
Exclusion Criteria:
- Secondary parkinsonism or atypical parkinsonian syndromes.
- Current use of anticholinergic medications.
- Contraindications to non-invasive electrical neuromodulation.
- Previous eTNS treatment within the past 6 months.
- Severe neurological, renal, cardiovascular, hepatic, or other major systemic diseases.
- Inability to complete clinical assessments or refusal to provide written informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: 40Hz-eTNS
40-Hz eTNS: frequency,40Hz; pulse width, 250 μs; duty cycle, 30 s on/30 s off; total stimulation duration, 20 min.
|
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication.
Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions.
Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Outros nomes:
|
|
Comparador Ativo: 120Hz-eTNS
120-Hz eTNS: frequency,120Hz; pulse width, 250 μs; duty cycle, 30 s on/30 s off; total stimulation duration, 20 min.
|
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication.
Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions.
Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Outros nomes:
|
|
Comparador Falso: sham-eTNS
Sham eTNS used a double-ramp paradigm with the same parameters as the 120-Hz condition(frequency,120Hz; pulse width, 250 μs; total stimulation duration, 20 min.),
but current was delivered only at stimulation onset (0-15 s) and midway through the session (15 s at 10 min).
|
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication.
Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions.
Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dual-Task Cost (DTC)
Prazo: DTC will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor based gait analysis system.
|
This is a within-subject study.
Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions.
After each eTNS condition, instrumented gait parameters will be collected during walking tasks.
Clinical rating scales will be additionally assessed after the final stimulation condition.Dual-task cost will be calculated as: [(single-task gait speed - dual-task gait speed) / single-task gait speed] × 100%.DTC reflects the reduction in walking performance under dual-task conditions relative to single-task conditions.
A decrease in DTC after eTNS indicates reduced dual-task interference during walking, suggesting that eTNS may reduce dual-task gait cost in patients with PD.
|
DTC will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor based gait analysis system.
|
|
Mean Gait Speed（m/s）
Prazo: Mean gait speed will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition. Mean gait speed will be directly obtained from the IDEEA system, which uses inertial sensors to quantitatively monitor gait during walking tasks in patients with PD. |
Mean gait speed will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
|
Mean Stride Length (m)
Prazo: Mean stride length will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
This is a within-subject study.
Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions.
After each eTNS condition, instrumented gait parameters will be collected during walking tasks.
Clinical rating scales will be additionally assessed after the final stimulation condition.
Mean stride length will be directly obtained from the IDEEA system, which uses inertial sensors to quantitatively monitor gait during walking tasks in patients with PD.
|
Mean stride length will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
stride frequency（steps/min）
Prazo: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
This is a within-subject study.
Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions.
After each eTNS condition, instrumented gait parameters will be collected during walking tasks.
Clinical rating scales will be additionally assessed after the final stimulation condition.Stride frequency will be recorded as directly generated by the IDEEA system.Improvement in stride frequency after eTNS suggests potential improvement in walking rhythm and gait control in patients with PD.
|
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
|
Double-support phase percentage（%）
Prazo: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.Double-support phase percentage will be calculated as: (double-support time / gait cycle time) × 100%. A higher Double-support phase percentage value generally indicates greater reliance on double-limb support to maintain stability, suggesting more cautious gait, impaired dynamic balance, and increased fall risk. A decrease in double-support phase percentage after eTNS suggests reduced dependence on double-limb support and potential improvement in gait stability and dynamic balance in patients with PD. |
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
|
gait symmetry index（%）
Prazo: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
This is a within-subject study.
Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions.
After each eTNS condition, instrumented gait parameters will be collected during walking tasks.
Clinical rating scales will be additionally assessed after the final stimulation condition.The symmetry index will be calculated as: |left-side gait parameter - right-side gait parameter| / [0.5 × (left-side gait parameter + right-side gait parameter)] × 100%.The symmetry index reflects the degree of difference between left- and right-side gait parameters and is used to evaluate bilateral gait symmetry.
A higher value indicates greater asymmetry, whereas a lower value indicates better gait symmetry.
A decrease in the symmetry index after eTNS suggests improved bilateral gait symmetry in patients with PD.
|
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hoehn and Yahr Scale
Prazo: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.The Hoehn and Yahr scale ranges from 1 to 5 in this study. Higher stages indicate more advanced disease and greater motor disability. It is a clinical staging system used to assess the overall severity of Parkinson's disease based on the distribution of motor symptoms, postural instability, walking ability, and functional disability. A higher stage indicates more severe disease. A decrease in Hoehn and Yahr scale after eTNS would suggest improvement in overall motor function and disease severity. |
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
|
Incidence of eTNS-Related Adverse Reactions [Safety and Tolerability]
Prazo: Throughout the experimental session, approximately 2.5-3 hours
|
Adverse reactions related to eTNS will be recorded throughout the experimental session, including local skin numbness, tingling, itching, redness at the electrode site, headache, dizziness, or any other discomfort reported by the participant or observed by the investigator.
The number and percentage of participants experiencing eTNS-related adverse reactions will be reported.
|
Throughout the experimental session, approximately 2.5-3 hours
|
|
Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III
Prazo: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III(MDS-UPDRS III) is a clinician-rated motor examination scale used to assess the severity of motor signs in Parkinson's disease, including rigidity, bradykinesia, tremor, gait, posture, and postural stability. The score ranges from 0 to 132, with each item rated from 0 to 4. Higher scores indicate more severe motor impairment.A decrease in the MDS-UPDRS Part III score after eTNS indicates improvement in motor function. |
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
|
Tinetti Gait Assessment
Prazo: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
This is a within-subject study.
Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions.
After each eTNS condition, instrumented gait parameters will be collected during walking tasks.
Clinical rating scales will be additionally assessed after the final stimulation condition.The Tinetti Gait Assessment score ranges from 0 to 12. Higher scores indicate better gait performance and stability.The Tinetti Gait Assessment evaluates gait performance during walking, including gait initiation, step length and height, step symmetry, step continuity, walking path, trunk stability, and walking stance.
A lower score indicates poorer gait function and greater gait instability, whereas a higher score indicates better gait function.
An increase in the Tinetti Gait Assessment score after eTNS suggests improvement in gait function in patients with PD.
|
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Sinucleinopatias
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Neurodegenerativas
- Distúrbios do Movimento
- Distúrbios parkinsonianos
- Doenças dos Gânglios da Base
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Manifestações Neurológicas
- Doença de Parkinson
Outros números de identificação do estudo
- LSS-K-2026-012-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Parkinson (DP)
-
Oxford Biodynamics Inc.Community Clinical Oncology Research Network, LLCRecrutamentoCâncer | Imunoterapia | PD-L1 | PD-1 | Terapia de checkpoint imunológicoEstados Unidos
-
Agenus Inc.ConcluídoCânceres Sólidos Avançados | Cânceres sólidos avançados refratários para terapias PD-1 e PD-L1Estados Unidos
-
Tianjin Medical UniversityTianjin Medical University General HospitalRecrutamentoMutação do gene PD-L1 | Tomografia por emissão de pósitrons | Amplificação do Gene PD-L1 | PD-L1-related DiseaseChina
-
The First Hospital of Jilin UniversityRecrutamentoMelanoma Mucoso | PD-L1 PositivoChina
-
Jiangsu vcare pharmaceutical technology co., LTDConcluídoSujeitos Saudáveis | PK/PDChina
-
University Hospital, MontpellierConcluídoPacientes recebendo imunoterapias anti-PD-1 ou anti-PD-L1França
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.DesconhecidoTumores Malignos PD-L1+ Recorrentes | Tumores malignos metastáticos PD-L1+China
-
Guohui LiRecrutamentoPD-1 | Eventos adversos relacionados à imunidadeChina
-
Wuxi People's HospitalRecrutamentoCâncer | Mutação do gene PD-L1China
-
Regeneron PharmaceuticalsRescindidoMalignidades Positivas PD-L1 AvançadasEstados Unidos